share_log

Regulus Therapeutics Analyst Ratings

Regulus Therapeutics Analyst Ratings

雷古勒斯治疗分析师评级
Benzinga ·  2023/08/10 04:51
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/10/2023 587.02% HC Wainwright & Co. → $9 Reiterates Buy → Buy
06/28/2023 587.02% HC Wainwright & Co. → $9 Reiterates Buy → Buy
06/21/2023 587.02% HC Wainwright & Co. → $9 Reiterates Buy → Buy
05/15/2023 587.02% HC Wainwright & Co. → $9 Reiterates Buy → Buy
04/21/2023 587.02% HC Wainwright & Co. $20 → $9 Maintains Buy
11/08/2022 587.02% Canaccord Genuity → $9 Initiates Coverage On → Buy
09/02/2021 52.67% Cantor Fitzgerald → $2 Initiates Coverage On → Overweight
05/14/2021 52.67% HC Wainwright & Co. $1.5 → $2 Maintains Buy
05/04/2020 14.5% HC Wainwright & Co. $2 → $1.5 Reiterates → Buy
09/06/2019 52.67% HC Wainwright & Co. → $2 Initiates Coverage On → Buy
03/19/2019 14.5% Wells Fargo $6 → $1.5 Maintains Market Perform
日期 上行/下行 分析公司 目标价格变动 评级变动 之前/当前的评级
08/10/2023 587.02% HC Wainwright & Co. → 9 美元 重申 购买 → 购买
06/28/2023 587.02% HC Wainwright & Co. → 9 美元 重申 购买 → 购买
06/21/2023 587.02% HC Wainwright & Co. → 9 美元 重申 购买 → 购买
05/15/2023 587.02% HC Wainwright & Co. → 9 美元 重申 购买 → 购买
04/21/2023 587.02% HC Wainwright & Co. 20 美元 → 9 美元 维护 购买
2022 年 8 月 11 日 587.02% Canaccord Genu → 9 美元 启动覆盖开启 → 购买
2021 年 2 月 9 日 52.67% 坎托·菲茨杰拉德 → 2 美元 启动覆盖开启 → 超重
05/14/2021 52.67% HC Wainwright & Co. 1.5 美元 → 2 美元 维护 购买
05/04/2020 14.5% HC Wainwright & Co. $2 → 1.5 美元 重申 → 购买
09/06/2019 52.67% HC Wainwright & Co. → 2 美元 启动覆盖开启 → 购买
03/19/2019 14.5% 富国银行 6 美元 → 1.5 美元 维护 市场表现

What is the target price for Regulus Therapeutics (RGLS)?

Regulus Therapeutics(RGLS)的目标价格是多少?

The latest price target for Regulus Therapeutics (NASDAQ: RGLS) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $9.00 expecting RGLS to rise to within 12 months (a possible 587.02% upside). 6 analyst firms have reported ratings in the last year.

HC Wainwright & Co. 于2023年8月10日公布了Regulus Therapeutics(纳斯达克股票代码:RGLS)的最新目标股价。这家分析公司将目标股价定为9.00美元,预计RGLS将在12个月内升至12个月内(可能上涨587.02%)。去年有6家分析公司公布了评级。

What is the most recent analyst rating for Regulus Therapeutics (RGLS)?

分析师对Regulus Therapeutics(RGLS)的最新评级是多少?

The latest analyst rating for Regulus Therapeutics (NASDAQ: RGLS) was provided by HC Wainwright & Co., and Regulus Therapeutics reiterated their buy rating.

Regulus Therapeutics(纳斯达克股票代码:RGLS)的最新分析师评级由HC Wainwright & Co. 提供,Regulus Therapeutics重申了他们的买入评级。

When is the next analyst rating going to be posted or updated for Regulus Therapeutics (RGLS)?

Regulus Therapeutics(RGLS)的下一个分析师评级何时公布或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regulus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regulus Therapeutics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Regulus Therapeutics的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月进行一次评级,因此每家公司每年应该获得4个评级。Regulus Therapeutics的最后一次评级是在2023年8月10日提交的,因此你应该预计下一个评级将在2024年8月10日左右公布。

Is the Analyst Rating Regulus Therapeutics (RGLS) correct?

分析师对 Regulus Therapeutics (RGLS) 的评级正确吗?

While ratings are subjective and will change, the latest Regulus Therapeutics (RGLS) rating was a reiterated with a price target of $0.00 to $9.00. The current price Regulus Therapeutics (RGLS) is trading at is $1.31, which is within the analyst's predicted range.

尽管评级是主观的,会发生变化,但Regulus Therapeutics(RGLS)的最新评级得到了重申,目标股价为0.00美元至9.00美元。Regulus Therapeutics(RGLS)目前的交易价格为1.31美元,在分析师的预测区间内。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发